VRTX · News · 20260908N
Acquisition / Partnership / Divestiture
VERTEX PHARMACEUTICALS INC / MA · 2026-09-08 · Importance 71 · Surprise 60 · No source text
Vertex Pharmaceuticals recently acquired Crinetics Pharmaceuticals for approximately $10 billion. The transaction expands Vertex’s portfolio beyond cystic fibrosis into rare-disease therapies. Third-party reporting characterizes the acquisition as part of Vertex’s strategy to diversify its pipeline and support renewed top-line growth as its core CF business slows.
Key facts
- Vertex Pharmaceuticals recently acquired Crinetics Pharmaceuticals for $10 billion. source
- Analyst projections ahead of Vertex's upcoming earnings report forecast a 10.36% increase in revenue. source
- Analyst projections ahead of Vertex's upcoming earnings report forecast 2.92% year-over-year growth in earnings per share. source
- On 2026-09-08, Vertex Pharmaceuticals (VRTX) stock closed down 3.15%. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| assets | positive | committed | +31.0% | Vertex Pharmaceuticals recently acquired Crinetics Pharmaceuticals for $10 billion. |
| revenue | positive | contingent | +1.6% | Analyst projections ahead of Vertex's upcoming earnings report forecast a 10.36% increase in revenue. |